Context.—Detailed diagnostic features of acute myeloid leukemia in Down syndrome are lacking, leading to potential misdiagnoses as standard acute myeloid leukemia occurring in patients with Down syndrome. Objective.—To evaluate diagnostic features of acute myeloid leukemia and myelodysplastic syndrome in patients with Down syndrome. Design.—Diagnostic bone marrow samples from 163 patients enrolled in the Children’s Oncology Group study AAML0431 were evaluated by using central morphologic review and institutional immunophenotyping. Results were compared to overall survival, event-free survival, GATA1 mutation status, cytogenetics, and minimal residual disease results. Results.—Sixty myelodysplastic syndrome and 103 acute myeloid leukemia samples were reviewed. Both had distinctive features compared to those of patients without Down syndrome. They showed megakaryocytic and erythroid but little myeloid dysplasia, and marked megakaryocytic hyperplasia with unusual megakaryocyte morphology. In acute myeloid leukemia cases, megakaryoblastic differentiation of blasts was most common (54 of 103, 52%); other cases showed erythroblastic (11 of 103, 11%), mixed erythroid/megakaryoblastic (20 of 103, 19%), or no differentiation (10 of 103, 10%). Myelodysplastic syndrome and acute myeloid leukemia cases had similar event-free survival and overall survival. Leukemic subgroups showed interesting, but not statistically significant, trends for survival and minimal residual disease. Cases with institutional diagnoses of French American British M1-5 morphology showed typical features of Down syndrome disease, with survival approaching that of other cases. Conclusions.—Myelodysplastic syndrome and acute myeloid leukemia in Down syndrome display features that allow discrimination from standard cases of disease. These distinctions are important for treatment decisions, and for understanding disease pathogenesis. We propose specific diagnostic criteria for Down syndrome–related subtypes of acute myeloid leukemia and myelodysplastic syndrome.
Bibliographical noteFunding Information:
This work was supported by National Institutes of Health (R01 CA120772), by the Children’s Oncology Group Operations Center Grant U10CA180886, by the Andrew McDonough B+ Foundation, by the St. Baldrick’s Foundation, and by the Children’s Oncology Group Statistics and Data Center grant (1U10CA180899).
This work was supported by National Institutes of Health (R01 CA120772), by the Children?s Oncology Group Operations Center Grant U10CA180886, by the Andrew McDonough B? Foundation, by the St. Baldrick?s Foundation, and by the Children?s Oncology Group Statistics and Data Center grant (1U10CA180899).
© 2020 College of American Pathologists. All rights reserved.